Key Highlights
- Windtree Therapeutics, Inc. signed an agreement for the sale of cardiovascular candidates.
- The company is set to receive $700,000 contingent on financing of at least $10 million.
- Windtree is entitled to 20% of future proceeds from the asset sale.
- Year-to-date, Windtree shares are down 66.7%, with a market capitalization of $1 million.
Windtree Therapeutics, Inc. (NASDAQ: WINT) has signed a significant agreement with Seismic Pharmaceutical Operations, LLC, potentially earning the company a payment of $700,000. This milestone could dramatically enhance Windtree's financial position, particularly given its challenging year, with shares down 66.7%. The deal involves the sale of its cardiovascular drug candidates, allowing the company to secure a future revenue stream of 20% on any proceeds from these assets, which could include significant revenues from global sales of drugs targeting acute heart failure (AHF).
The timing of this agreement is critical for Windtree, currently grappling with a share price that has fallen 50.0% in the last month and a market capitalization of just $1 million.
Key Agreement Details
Windtree's new partnership with Seismic Pharmaceuticals includes the sale of its promising cardiovascular drug candidates, with the agreement stipulating that Windtree will receive 20% of any global commercial net revenue from these products, pending regulatory approval. In addition to this revenue share, the company stands to gain $700,000 from Seismic Pharmaceutical, contingent upon the completion of a financing round exceeding $10 million. Windtree will also transfer over certain development payables related to these drug candidates to its new partner.
This arrangement marks Windtree's 19th material agreement disclosure since its last major announcement, underlining the company's strategy to realign its asset portfolio and financial outlook.
Market Context and Performance
Windtree's stock has faced intense downward pressure, marked by a staggering 66.7% decline year-to-date and a recent 50.0% drop over the past month. The shares currently trade at $0.01, a stark contrast to the 52-week range that peaked at $1.20. The market capitalization stands at approximately $1 million, reflecting investor sentiment amid the company's restructuring efforts.
As Windtree seeks to capitalize on its partnership with Seismic, this agreement may provide necessary funding and support in a important growth area, cardiovascular innovation where there is substantial unmet need. The market for these drugs could reach billions, making the potential revenue streams significant for Windtree.
Future Watch
Investors should closely monitor follow-up developments from Windtree's agreement with Seismic Pharmaceuticals, with particular attention to the anticipated financing round above $10 million, which could unlock the $700,000 payment linked to the deal. The execution of this financing is critical; should it succeed, the resulting cash influx would assist Windtree in furthering its research and development efforts without additional dilution of existing shares. The next key step will be the completion of the financing and actualized revenue from the newly acquired cardiovascular assets, expected within the coming months.
Evolving actions in this rapidly shifting environment will be fundamental to gauging investor sentiment and stock performance.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...